What is claimed is:

1. An isolated human antibody or antibody fragment comprising one or more complementarity determining regions selected from the group consisting of SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; SEQ ID NO:6 at CDRH3; SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.

- 2. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; and SEQ ID NO:6 at CDRH3.
- 3. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:8.
- 4. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.
- 5. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:16.
- 6. The antibody or antibody fragment of Claim 1, which comprises SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; SEQ ID NO:6 at CDRH3; SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.
- 7. The antibody or antibody fragment of Claim 1, which comprises SEQ ID NO:8 and SEQ ID NO:16.
- 8. The antibody or antibody fragment of any one of Claims 1 to 7, which binds selectively to EGFR.
- 9. The antibody or antibody fragment of any one of Claims 1 to 7, which inhibits binding of EGFR to a ligand of EGFR.
- 10. The antibody or antibody fragment of any one of Claims 1 to 7, which neutralizes EGFR.
- 11. The antibody fragment of any one of Claims 1 to 7, which is selected from the group consisting of a single chain antibody, an Fab, a single chain Fv, a diabody, and a triabody.

12. A conjugate of the antibody or antibody fragment of any one of Claims 1 to 7.

- 13. The conjugate of Claim 12, which comprises an anti-neoplastic agent, a target moiety or a reporter moiety.
- 14. An isolated polynucleotide which encodes an antibody or antibody fragment and comprises one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 1 at CDRH1; SEQ ID NO:3 at CDRH2; SEQ ID NO:5 at CDRH3; SEQ ID NO:9 at CDRL1; SEQ ID NO:11 at CDRL2; and SEQ ID NO:13 at CDRL3.
 - 15. The isolated polynucleotide of Claim 14, which comprises SEQ ID NO:7.
 - 16. The isolated polynucleotide of Claim 14, which comprises SEQ ID NO:15.
- 17. An expression vector comprising the polynucleotide of any one of Claims 14 to 16.
 - 18. A recombinant host cell comprising the expression vector of Claim 17.
- 19. The recombinant host cell of Claim 18 which produces a polypeptide comprising SEQ ID NO:8 and a polypeptide comprising SEQ ID NO:16.
- 20. The recombinant host cell of Claim 18 which produces a polypeptide comprising SEQ ID NO:8 and SEQ ID NO:16.
- 21. A method of inhibiting tumor growth in a mammal comprising administering a therapeutically effective amount of the antibody of any one of Claims 1 to 11.
 - 22. The method of Claim 21, wherein the tumor expresses EGFR.
 - 23. The method of Claim 21, wherein the tumor overexpresses EGFR.
 - 24. The method of Claim 21, wherein the tumor is a primary tumor.
 - 25. The method of Claim 21, wherein the tumor is a metastatic tumor.

26. The method of Claim 21, wherein the tumor is a refractory tumor.

- 27. The method of Claim 21, wherein the tumor is a vascularized tumor.
- 28. The method of Claim 21, wherein the tumor is selected from the group consisting of a colorectal tumor, a head and neck tumor, a pancreatic tumor, a lung tumor, a breast tumor, a renal cell carcinoma, and a glioblastoma.
- 29. The method of Claim 21, wherein the antibody or antibody fragment is administered in combination with an anti-neoplastic agent.
- 30. The method of Claim 29, wherein the antineoplastic agent is a chemotherapeutic agent.
- 31. The method of Claim 29, wherein the aritineoplastic agent is irinotecan (CPT-11).
 - 32. The method of Claim 29, wherein the antineoplastic agent is radiation.
- 33. The method of Claim 21, wherein the antibody or antibody fragment is administered with an EGFR antagonist.
- 34. The method of Claim 33, wherein the EGFR antagonist is an intracellular EGFR antagonist.
- 35. The method of Claim 21, which further comprises administration of a therapeutically effective amount of a vascular endothelial factor receptor (VEGFR) antagonist.
- 36. The method of Claim 21, which further comprises administration of a therapeutically effective amount of an insulin like growth factor receptor (IGFR) antagonist.
- 37. A method of treating a hyperproliferative disease comprising administering a therapeutically effective amount of an antibody of any one of Claims 1 to 11.
- 38. The method of Claim 37, wherein the hyperproliferative disease is psoriasis.

39. The method of Claim 38, wherein the antibody or antibody fragment is administered in combination with a topical or systemic agent for psoriasis

- 40. The method of Claim 38, wherein the antibody or antibody fragment is administered in combination with a corticosteroid.
- 41. The method of Claim 38, wherein the antibody of antibody fragment is administered in combination with a retinoid.